Study of Effectiveness of Mexyn-A (Mexyn-A)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00568204
Recruitment Status : Completed
First Posted : December 5, 2007
Last Update Posted : October 17, 2013
Information provided by:
Evangelical Synod Medical Centre

November 30, 2007
December 5, 2007
October 17, 2013
March 2002
Not Provided
Treating Pruritus [ Time Frame: three days ]
Same as current
Complete list of historical versions of study NCT00568204 on Archive Site
measuring itch-free period after applying the new treatment, effect on sleep disturbance [ Time Frame: three days ]
Same as current
Not Provided
Not Provided
Study of Effectiveness of Mexyn-A
Proof of Concept of MEXYN-A
Atomised Methoxymethane-in-Aqua (MEXYN-A) a new topical self-chilled, non-steroidal, non-flammable, pressurised spray which embodies in one simultaneous application, most of the currently recognised and effective chemical, mechanical and thermal anti-pruritic therapies and hydrotherapy.
The primary clinical endpoint was to establish MEXYN-A efficacy and safety in abolishing or reducing pruritus related to cutaneous diseases, insect bites and poison ivy, within few seconds of the application. The secondary endpoint was to measure the itch free period as a result of the new intervention.
Not Applicable
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Device: Mexyn-A
Atomised topical self-chilled pressurised spray
Other Name: Clearitch, Itcharret, itchclear, Magicool-Plus
Experimental: 1
Intervention: Device: Mexyn-A
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
September 2005
Not Provided

Inclusion Criteria:

  • Patients suffering from severe itching due to : Atopic Dermatitis, contact dermatitis, psoriasis, urticaria, xerosis, prickly heat, genital pruritus, chicken pox, aquagenic pruritus, lichen planus, poison ivey, insect bites.
  • Past experience with the use of at least one conventional medication for pruritus or conventional medication for the same disorder patients suffered.

Exclusion Criteria:

  • Patients who have taken any anti-pruritic drug during the month prior to participation.
  • Patients who have taken drugs for any reason for 2 days prior to participating in the study.
Sexes Eligible for Study: All
5 Years to 80 Years   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Dr Ihab Akhnoukh M.D., Evangelical Synod Medical Centre
Evangelical Synod Medical Centre
Not Provided
Principal Investigator: Ihab Akhnoukh Evangelical Synod Medical Centre
Study Director: Ashraf Khella Harpur Memorial Hospital
Evangelical Synod Medical Centre
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP